p53 and PTEN expression evaluation with molecular evident recent criteria in laryngeal carcinoma
Rattachement africain : tr. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
The prognosis of laryngeal cancer is affected by clinicopathological factors. Because of that, an effective prognostic marker is very valuable in managing the clinical process. The p53 evaluation method, used in the literature recently, was used for the first time in laryngeal cancer. We evaluated PTEN with 2 methods with the highest significance in the literature on laryngeal cancer. All demographic and histopathological data from 140 laryngeal cancers were compared with p53 and PTEN expressions and survival. p53 staining patterns were classified as wild and mutant. PTEN expression was evaluated according to the staining intensity named PTEN1 and according to the proportion of stained cells named PTEN2. In the series, 93.6% were males, and the mean survival was 38 months. 69.3% of cases were p53 mutants. PTEN loss was found to be 85.7% and 57.9%, respectively. Tumor size and thyroid cartilage invasion for PTEN1 and age for p53 were identified as independent predictive factors (P < .01). Advanced age, total laryngectomy, and extranodal spread were independent poor prognostic factors for overall survival and the presence of subglottic involvement, perineural invasion, and extranodal spread were for disease-free survival (P < .01). This is the first study in which the new p53 classification was used in laryngeal cancer, and will contribute significantly to the literature with differences from the previous evaluation patterns. Evaluation of PTEN based on staining intensity is more appropriate compared to the percentage of stained cells.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- p53 and PTEN expression evaluation with molecular evident recent criteria in laryngeal carcinoma
- Date Crossref
- 12/05/2023
- Éditeur
- Ovid Technologies (Wolters Kluwer Health)
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Manisa Celal Bayar University Department of Pathology pays non établi dans la noticeUniversité ou école supérieure
-
Dokuz Eylül University Department of Molecular Pathology pays non établi dans la noticeUniversité ou école supérieure
-
102:19(e33676) pays non établi dans la noticeInstitution
-
All data generated or analyzed during this study are included in this published article [and its supplementary information files] pays non établi dans la noticeEntreprise
-
How to cite this article: Tan A pays non établi dans la noticeInstitution
Department of Pathology — Manisa Celal Bayar University, Department of Molecular Pathology — Dokuz Eylül University et 102:19(e33676), avec 2 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.